###### Strengths and limitations of this study

-   This systematic review will explore a novel and covert clinical area.

-   It will comprehensively assess existing literature that investigates associations between bipolar spectrum disorder and bone health.

-   Potential confounders and/or mediators of the relationship will be identified.

-   Two authors will independently confirm study selection, and undertake data extraction and methodological assessment.

-   A potential limitation of this review may be the paucity of data available due to this being a nascent area of enquiry, and that there may be much heterogeneity in available studies.

Introduction {#s1}
============

Bipolar spectrum disorder, a mental disorder characterised by biphasic fluctuations in mood, is a severe, chronic, episodic illness, which generally necessitates pharmacotherapy and/or psychotherapy. It is estimated to affect ∼2.4% of the population[@R1] and has been ranked the sixth leading cause of disability in the world, among individuals aged 15--44 years.[@R2] The related direct and indirect costs associated with bipolar spectrum disorder are substantial.[@R3] [@R4] The burden of bipolar spectrum disorder is experienced on many levels---by the sufferer, their immediate family and friends and also by the healthcare system. Symptom burden and disease course is often worsened in the presence of psychological and/or physiological comorbidities.[@R5] [@R6]

Psychiatric disorders, including bipolar spectrum disorder, have been associated with early mortality, with ∼60% of this excess mortality due to chronic physical illness.[@R7] A particularly common comorbidity of unipolar depression is osteoporosis.[@R8] [@R9] Yet it is normatively overlooked, due to being asymptomatic until fracture occurs. Osteoporosis is a global public health issue, estimated to affect nearly 49 million individuals in industrialised countries, with this on the rise as a consequence of the ageing population.[@R10] [@R11] The rising global economic burden related to the direct and indirect costs of medical care and rehabilitation of individuals with osteoporotic fractures is concerning.[@R12] [@R13] Both clinically diagnosed unipolar depression and depressive symptoms have been shown to be associated with deficits in bone mineral density (BMD), bone loss over time and increased fracture risk in men and women.[@R9] [@R14] [@R15] Furthermore, antidepressants, in particular, selective serotonin reuptake inhibitors used in treatment of depression, have also been shown to be noxious to bone.[@R16] Other psychotropic medication, namely antipsychotics and anticonvulsants, have also been shown to have a deleterious effect on bone.[@R17] A recent research synthesis with meta-analyses concluded that depression should be considered a serious risk factor for osteoporosis, based on aggregated data showing BMD among individuals with depression to be up to 7.3% lower.[@R15] [@R20] Another meta-analysis reported depression to be associated with up to a 52% increased risk of fracture.[@R21] Whether this is true for bipolar spectrum disorder per se is yet to be determined.

Considering the previous research discussing the probable association between unipolar depression and bone, this review would essentially provide a starting point for similar investigations in bipolar spectrum disorder. This review will analyse the existing data, and this information may provide a clearer background into bone fragility associated with bipolar spectrum disorder, enabling the details of this association to be further explored.

Objectives {#s1a}
----------

This systematic review will: Identify published studies that investigate the association between bipolar spectrum disorder and bone health, including BMD and fracture;Evaluate the quality of the methodology used in each of the studies eligible for inclusion in this review;Collate the evidence, including identifying any potential confounding and/or mediating factors in the association between bipolar spectrum disorder and bone health;Perform sensitivity analyses to account for differences between (a) self-reported and diagnosed bipolar spectrum disorder, (b) diagnostic criteria between versions of the Diagnostic and Statistical Manual (DSM) and/or International Classification of Diseases (ICD) and (c) bipolar disorders I and II;Provide a comprehensive synthesis of the findings using previously published methodology.

Methods {#s2}
=======

Criteria for considering studies for this review {#s2a}
------------------------------------------------

Articles resulting from cross-sectional, case--control and/or longitudinal studies of bone health (defined as BMD, bone quality, osteoporosis and/or fracture), in adult populations (≥18 years) with bipolar spectrum disorder (defined by self-report, medical records or diagnoses based on any version of the Diagnostic and Statistical Manual of Mental Disorders or International Statistical Classification of Diseases and Related Health Problems criteria), inclusive of any sex or nationality, and published in any year, will be considered as eligible for this review.

Grey literature, case studies, theses and conference presentations will be excluded. Baseline data from randomised control trials will be included and treated as cross-sectional analyses.

Search strategy and data extraction {#s2b}
-----------------------------------

In order to identify the relevant literature, we will undertake an electronic search strategy to investigate research databases from the disciplines of medical, health and the social sciences (PubMed, OVID, CINAHL, MEDLINE). The following medical subject headings will be applied: "bipolar disorder" AND ("bone" OR "osteoporosis" OR "fracture" OR "bone density"), to identify publications that match our eligibility criteria. For our search strategy, we will also include the key word term of 'bipolar spectrum disorder'.

No limits will be applied with regard to year of publication. For each database, where appropriate, relevant truncation will be applied. One reviewer will apply the search strategy and identify eligible literature for inclusion by cross-checking with the predetermined eligibility criteria. Two further reviewers will confirm the eligibility of those identified articles. Professional assistance would be sought to interpret articles written in languages other than English, in order to confirm their relevance to the eligibility criteria. Finally, the reference lists of eligible studies will be manually searched by two reviewers.[@R22]

Assessment of methodological quality of included articles {#s2c}
---------------------------------------------------------

The methodological scoring system of Lievense *et al*[@R23] will be employed to assess the methodological quality of included articles ([tables 1](#BMJOPEN2016013981TB1){ref-type="table"} and [2](#BMJOPEN2016013981TB2){ref-type="table"}). Based on those methodological assessment criteria, each eligible study will be scored, with each study given either a positive or negative score for each criterion. This process of scoring methodological quality reflects cohort studies as the most optimal study design, followed by case--control studies and, finally, cross-sectional study designs. Two reviewers will independently score the methodological quality of each study; should these scores differ, the reviewers will attempt to reconcile any differences, after which a third reviewer would provide final judgement, if necessary. Each study will be ranked according to their total score (%), and deemed as having higher methodological quality if scored above the median, as previously published.[@R24]

###### 

Criteria list for assessment of study quality, adapted from Lievense *et al*[@R23]

  Item                             Criterion                                                                      C/CC/CS
  -------------------------------- ------------------------------------------------------------------------------ ---------
  Study population                                                                                                
  1                                Uniform point (selection before disease was present)                           C/CC/CS
  2                                Cases and controls drawn from the same population                              CC
  3                                Participation rate \>80% for cases/cohort                                      C/CC/CS
  4                                Participation rate\>80% for controls                                           CC
  Assessment of risk factor                                                                                       
  5                                Exposure assessment blinded                                                    C/CC/CS
  6                                Exposure measured identically for cases and controls                           CC
  7                                Exposure assessed prior to the outcome                                         C/CC/CS
  Assessment of outcome                                                                                           
  8                                Bone health assessed identically in patients with bipolar spectrum disorder.   C/CC/CS
  9                                Presence of osteoporosis assessed reproducibly                                 C/CC/CS
  10                               Osteoporosis identification assessed according to BMD measurements             C/CC/CS
  Study design                                                                                                    
  11                               Prospective design used                                                        C/CC
  12                               Follow-up time \>24 months                                                     C
  13                               Withdrawals \<20%                                                              C
  Analysis and data presentation                                                                                  
  14                               Appropriate analysis techniques used                                           C/CC/CS
  15                               Adjusted for at least age and sex                                              C/CC/CS

BMD, bone mineral density; C, applicable to cohort studies; CC, applicable to case--control studies; CS, applicable to cross-sectional.

###### 

Method for determining the level of evidence for best evidence synthesis, adapted from Lievense *et al*; replicated from Brennan *et al*[@R24]

  ---------------------- ------------------------------------------------------------------------------------------------------------------------------------------------
  Level of evidence      Criteria for inclusion in best evidence synthesis
  Strong evidence        Generally consistent findings in: Multiple high-quality cohort studies
  Moderate evidence      Generally consistent findings in: 1 high-quality cohort study and \>2 high-quality case--control studies\>3 high-quality case--control studies
  Limited evidence       Generally consistent findings in: A single cohort study1 or 2 case--control studies orMultiple cross-sectional studies
  Conflicting evidence   Inconsistent findings in \>25% of the trials
  No evidence            No studies could be found
  ---------------------- ------------------------------------------------------------------------------------------------------------------------------------------------

For the meta-analyses, we will determine the population with bipolar spectrum disorder to be our proxy 'treatment' group and apply Hunter-Schmidt\'s approach,[@R25] whereby a pooled within-group SD will be used. Effect size will be corrected for measurement error by dividing the effect size by the square root of the reliability coefficient of the dependent variable, whereby measurement error correction equals the effect size divided by the square root of r.

Presenting and reporting results {#s2d}
--------------------------------

PRISMA guidelines[@R26] will be adhered to, with regard to the presentation of findings from this review, and this protocol adheres to the PRISMA-P guidelines.[@R27] Numbers and reasons pertaining to inclusion versus exclusion of papers in the context of the predetermined eligibility criteria will be presented in a QUOROM diagram.[@R28] Key information regarding factors involved in the association between bipolar spectrum disorder and bone health will be identified; these factors may include, but will not be limited to, inflammatory markers, lifestyle behaviours, socioeconomic status, medications and substance use. Our findings will be useful to inform and reach a consensus as to the link between bipolar spectrum disorder and bone health.

A meta-analysis is planned; however, if a numerical synthesis is not possible due to methodological heterogeneity, a 'best evidence synthesis' will be undertaken. A 'best evidence synthesis' would evaluate the level of evidence identified, ranging from no evidence to strong evidence ([table 2](#BMJOPEN2016013981TB2){ref-type="table"}), as previously published in the musculoskeletal field.[@R24]

We will also perform sensitivity analyses to account for differences between (1) self-reported and diagnosed bipolar spectrum disorder, (2) diagnostic criteria between versions of the DSM and/or ICD and (3) bipolar disorders I and II.

Dissemination {#s2e}
-------------

This protocol will be registered with PROSPERO, an international database of health-related systematic review protocols. The findings of our systematic review will be published in a peer-reviewed scientific journal, and results will be shared at national and/or international conferences relevant to the field of bipolar spectrum disorder and/or bone health.

Ethics {#s2f}
------

Since only published data will be used in this systematic review, we do not require ethical permission. However, ethical and governance standards will be strictly adhered to, in matters of data management and in the presentation and discussion of our results.

Conclusion {#s2g}
----------

To the best of our knowledge, this will be the first systematic review to identify and evaluate the existing evidence base regarding associations between bipolar spectrum disorder and bone health; and determining the nature of this relationship has both public health and clinical implications. The findings of this review will contribute to existing literature investigating other psychiatric disorders and bone health, and will also provide an evidence base on which resource allocation and clinical and public health strategies aimed at reducing burden associated with both osteoporosis and bipolar spectrum disorder can be founded.
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